Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Molnupiravir and Its Antiviral Activity Against COVID-19
Lili Tian, Zehan Pang, Maochen Li, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 102

Showing 1-25 of 102 citing articles:

Real-world effectiveness of molnupiravir and nirmatrelvir plus ritonavir against mortality, hospitalisation, and in-hospital outcomes among community-dwelling, ambulatory patients with confirmed SARS-CoV-2 infection during the omicron wave in Hong Kong: an observational study
Carlos King Ho Wong, Ivan Chi Ho Au, Kristy T. K. Lau, et al.
The Lancet (2022) Vol. 400, Iss. 10359, pp. 1213-1222
Open Access | Times Cited: 243
Real-world effectiveness of early molnupiravir or nirmatrelvir–ritonavir in hospitalised patients with COVID-19 without supplemental oxygen requirement on admission during Hong Kong's omicron BA.2 wave: a retrospective cohort study
Carlos King Ho Wong, Ivan Chi Ho Au, Kristy T. K. Lau, et al.
The Lancet Infectious Diseases (2022) Vol. 22, Iss. 12, pp. 1681-1693
Open Access | Times Cited: 218
Small molecules in the treatment of COVID-19
Sibei Lei, Xiaohua Chen, Jieping Wu, et al.
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 78
A Review of the Antibacterial, Fungicidal and Antiviral Properties of Selenium Nanoparticles
Dmitriy A. Serov, Venera V. Khabatova, Vladimir Vodeneev, et al.
Materials (2023) Vol. 16, Iss. 15, pp. 5363-5363
Open Access | Times Cited: 52
Nitazoxanide and COVID-19: A review
Hayder M. Al‐kuraishy, Ali I. Al‐Gareeb, Engy Elekhnawy, et al.
Molecular Biology Reports (2022) Vol. 49, Iss. 11, pp. 11169-11176
Open Access | Times Cited: 41
Feline Infectious Peritonitis: European Advisory Board on Cat Diseases Guidelines
Séverine Tasker, Diane Addie, Herman Egberink, et al.
Viruses (2023) Vol. 15, Iss. 9, pp. 1847-1847
Open Access | Times Cited: 32
Molnupiravir: A Versatile Prodrug against SARS-CoV-2 Variants
Divya Teli, Pankti C. Balar, Kishan Patel, et al.
Metabolites (2023) Vol. 13, Iss. 2, pp. 309-309
Open Access | Times Cited: 25
A retrospective cohort study on early antibiotic use in vaccinated and unvaccinated COVID‐19 patients
Carlo Brogna, Luigi Montano, Maria Elisabetta Zanolin, et al.
Journal of Medical Virology (2024) Vol. 96, Iss. 3
Open Access | Times Cited: 9
Small Molecule Drugs Targeting Viral Polymerases
Deborah Palazzotti, Martina Sguilla, Giuseppe Manfroni, et al.
Pharmaceuticals (2024) Vol. 17, Iss. 5, pp. 661-661
Open Access | Times Cited: 7
Medicinal chemistry strategies towards the development of non-covalent SARS-CoV-2 Mpro inhibitors
Letian Song, Shenghua Gao, Bing Ye, et al.
Acta Pharmaceutica Sinica B (2023) Vol. 14, Iss. 1, pp. 87-109
Open Access | Times Cited: 19
Targeting SARS-CoV-2 Non-Structural Proteins
W.G. Tam, Ana C. Lorenzo‐Leal, Luis R. Hernández, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 16, pp. 13002-13002
Open Access | Times Cited: 16
Ecofriendly bioanalytical validated RP-HPLC method for simultaneous determination of COVID-19 co-prescribed drugs employing quality by design and green chemistry
Sohair mohamed aboelghar, Maha A. Hegazy, Hebatallah A. Wagdy
Microchemical Journal (2024) Vol. 200, pp. 110292-110292
Closed Access | Times Cited: 6
New perspective of small-molecule antiviral drugs development for RNA viruses
Shasha Li, Huixia Li, Ruiya Lian, et al.
Virology (2024) Vol. 594, pp. 110042-110042
Closed Access | Times Cited: 5
Transformative Approaches in SARS-CoV-2 Management: Vaccines, Therapeutics and Future Direction
Ankita Saha, Shweta Choudhary, Priyanshu Walia, et al.
Virology (2025) Vol. 604, pp. 110394-110394
Closed Access
Rapid luminescence-based screening method for SARS- CoV-2 inhibitors discovery
Abdeldjalil Madani, Nadine Álvarez, Steven Park, et al.
SLAS DISCOVERY (2025) Vol. 31, pp. 100211-100211
Open Access
Comparison of greenness and blueness assessments for analytical methods used in the analysis of ritonavir, favipiravir, and molnupiravir: Applications in different matrices
Christine K. Nessim, Abdulsalam Ashkar, Bahga M. El-Zablaawy, et al.
Microchemical Journal (2025), pp. 113165-113165
Closed Access
Sub‐lineages of the SARS‐CoV‐2 Omicron variants: Characteristics and prevention
Ailan Xu, Bixia Hong, Fuxing Lou, et al.
MedComm (2022) Vol. 3, Iss. 3
Open Access | Times Cited: 25
SARS-CoV-2 proteases Mpro and PLpro: Design of inhibitors with predicted high potency and low mammalian toxicity using artificial neural networks, ligand-protein docking, molecular dynamics simulations, and ADMET calculations
Roman S. Tumskiy, Anastasiia V. Tumskaia, Iraida Nikolaevna Klochkova, et al.
Computers in Biology and Medicine (2022) Vol. 153, pp. 106449-106449
Open Access | Times Cited: 24
Real-world effectiveness of early molnupiravir and nirmatrelvir/ritonavir among hospitalized, non-oxygen-dependent COVID-19 patients on admission during Hong Kong’s Omicron BA.2 wave: an observational study
Carlos King Ho Wong, Ivan Chi Ho Au, Kristy T. K. Lau, et al.
medRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access | Times Cited: 22
Efficacy and safety of molnupiravir for COVID-19 patients
Maurish Fatima, Saleha Azeem, Junaid Saeed, et al.
European Journal of Internal Medicine (2022) Vol. 102, pp. 118-121
Open Access | Times Cited: 22
A proof-of-concept study on the genomic evolution of Sars-Cov-2 in molnupiravir-treated, paxlovid-treated and drug-naïve patients
Claudia Alteri, Valeria Fox, Rossana Scutari, et al.
Communications Biology (2022) Vol. 5, Iss. 1
Open Access | Times Cited: 22
Potential Anti-SARS-CoV-2 Prodrugs Activated by Phosphorylation and Their Role in the Aged Population
Vivek P. Chavda, Divya Teli, Pankti C. Balar, et al.
Molecules (2023) Vol. 28, Iss. 5, pp. 2332-2332
Open Access | Times Cited: 13
Drug Resistance: An Incessant Fight against Evolutionary Strategies of Survival
Francisco Ramos‐Martín, Nicola D′Amelio
Microbiology Research (2023) Vol. 14, Iss. 2, pp. 507-542
Open Access | Times Cited: 13
Clinical effectiveness of oral antiviral agents in older patients with COVID‐19 based on real‐world data
Ya‐Wen Tsai, Jheng‐Yan Wu, Tinghui Liu, et al.
Journal of Medical Virology (2023) Vol. 95, Iss. 6
Closed Access | Times Cited: 13
Molnupiravir maintains antiviral activity against SARS-CoV-2 variants and exhibits a high barrier to the development of resistance
Julie Strizki, John M. Gaspar, John A. Howe, et al.
Antimicrobial Agents and Chemotherapy (2023) Vol. 68, Iss. 1
Open Access | Times Cited: 13
Page 1 - Next Page

Scroll to top